Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To estimate budget impact of adopting lesinurad as add-on to allopurinol for urate-lowering therapy in gout. Methods: A budget impact model was developed for a US payer perspective, using a Markov model to estimate costs, survival and discontinuation in a one-million-member health plan. The population included patients failing first-line gout therapy, followed for 5 years. Results: Incremental costs of adding lesinurad versus no lesinurad were US$241,907 and US$1,098,220 in first and fifth years, respectively. Cumulative 5-year incremental cost was US$3,633,440. Estimated incremental mean cost per treated patient with gout per year was US$112. The mean per-member per-month cost increased by US$0.06. Conclusion: Initiating lesinurad would result in an incremental per-member per-month cost of US$0.06 over 5 years.
Supplementary Material
File (suppl_data.docx)
- Download
- 54.72 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 63(10), 3136–3141 (2011).
• Estimate of the national prevalence of gout in the US population.
2.
Chhana A, Callon KE, Dray M et al. Interactions between tenocytes and monosodium urate monohydrate crystals: implications for tendon involvement in gout. Ann. Rheum. Dis. 73(9), 1737–1741 (2014).
3.
Dalbeth N, Clark B, Gregory K et al. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann. Rheum. Dis. 68(8), 1290–1295 (2009).
4.
Dalbeth N, Aati O, Kalluru R et al. Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study. Ann. Rheum. Dis. 74(6), 1030–1036 (2015).
5.
Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann. Rheum. Dis. 74(4), 661–667 (2015).
6.
Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 48(Suppl. 2), ii2–ii8 (2009).
7.
Boss GR, Seegmiller JE. Hyperuricemia and gout. Classification, complications and management. N. Engl. J. Med. 300(26), 1459–1468 (1979).
8.
Chen JH, Lan JL, Cheng CF et al. Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study. J. Rheumatol. 42(9), 1694–1701 (2015).
9.
Kleber ME, Delgado G, Grammer TB et al. Uric acid and cardiovascular events: a Mendelian randomization study. J. Am. Soc. Nephrol. 26(11), 2831–2838 (2015).
10.
Niskanen LK, Laaksonen DE, Nyyssonen K et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch. Intern. Med. 164(14), 1546–1551 (2004).
11.
Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis 231(1), 61–68 (2013).
12.
Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res. Ther. 17, 90 (2015).
13.
Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann. Rheum. Dis. 73(1), 177–182 (2014).
14.
Stack AG, Hanley A, Casserly LF et al. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 106(7), 647–658 (2013).
15.
The United States Bone and Joint Initiative. Chapter 4: Arthritis. In: The Burden Of Musculoskeletal Diseases In The United States (3rd Ed.). IL, USA (2014).
16.
Rai SK, Burns LC, De Vera MA, Haji A, Giustini D, Choi HK. The economic burden of gout: A systematic review. Semin. Arthritis Rheum. 45(1), 75–80 (2015).
17.
Cisternas MG, Murphy LB, Pasta DJ, Yelin EH, Helmick CG. Annual medical care expenditures among US adults with gout, 2005–2011. Arthritis Rheum. 66(S10), S888–S888 (2014).
18.
Wertheimer A, Morlock R, Becker MA. A revised estimate of the burden of illness of gout. Curr. Ther. Res. Clin. Exp. 75, 1–4 (2013).
19.
Kabadi S, Myers J, Bly C. Health economics of uncontrolled gout in the United States: a systematic literature review. Presented at: ACR/ARHP Annual Meeting. Washington, DC, USA, 11–16 November 2016.
20.
Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related quality of life in gout: a systematic review. Rheumatology (Oxford) 52(11), 2031–2040 (2013).
• Assessment of the health-related quality of life in gout patients.
21.
Khanna D, Fitzgerald JD, Khanna PP et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken) 64(10), 1431–1446 (2012).
•• The current US guidelines for treatment of gout.
22.
Dubchak N, Falasca GF. New and improved strategies for the treatment of gout. Int. J. Nephrol. Renovasc. Dis. 3, 145–166 (2010).
23.
24.
25.
White WB, Saag KG, Becker MA et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N. Engl. J. Med. 378(13), 1200–1210 (2018).
26.
Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 44(8), 1038–1042 (2005).
27.
Reach G. Treatment adherence in patients with gout. Joint Bone Spine 78(5), 456–459 (2011).
28.
Becker MA, Schumacher HR, Jr., Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353(23), 2450–2461 (2005).
29.
Becker MA, Schumacher HR, Espinoza LR et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res. Ther. 12(2), R63 (2010).
30.
Schumacher HR Jr, Becker MA, Wortmann RL et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, Phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59(11), 1540–1548 (2008).
31.
US Food and Drug Administration. Allopurinol drug details: FDA approved drug products. (2017). www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203154
32.
Becker MA, Chohan S. We can make gout management more successful now. Curr. Opin. Rheumatol. 20(2), 167–172 (2008).
33.
Hainer BL, Matheson E, Wilkes RT. Diagnosis, treatment, and prevention of gout. Am. Fam. Physician 90(12), 831–836 (2014).
34.
Miner J, Tan PK, Hyndman D et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res. Ther. 18(1), 214 (2016).
35.
Bardin T, Keenan RT, Khanna PP et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann. Rheum. Dis. 76(5), 811–820 (2016).
•• One of two Phase III trials of lesinurad in combination with allopurinol that demonstrated the superior serum uric acid–lowering efficacy of combination treatment.
36.
Saag KG, Fitz-Patrick D, Kopicko J et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol. 69(1), 203–212 (2017).
•• One of two Phase III trials of lesinurad in combination with allopurinol that demonstrated the superior serum uric acid–lowering efficacy of combination treatment.
37.
National Institute for Health and Care Excellence. Lesinurad for treating chronic hyperuricaemia in people with gout. Technology appraisal guidance [TA506] (2018). www.nice.org.uk/guidance/ta506
38.
Juraschek SP, Kovell LC, Miller ER, Iii., Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res. (Hoboken) 67(4), 588–592 (2015).
39.
Becker MA, Schumacher HR, Macdonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J. Rheumatol. 36(6), 1273–1282 (2009).
40.
Khanna D, Khanna PP, Fitzgerald JD et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. (Hoboken) 64(10), 1447–1461 (2012).
41.
Becker MA, Fitz-Patrick D, Choi HK et al. An open-label, 6-month study of allopurinol safety in gout: the LASSO study. Semin. Arthritis Rheum. 45(2), 174–183 (2015).
42.
Truven Health Analytics. RED BOOK Online®. Micromedex Solutions (2017).
43.
US Bureau of Labor Statistics. Consumer Price Index (CPI) all urban consumers. (2016). www.bls.gov/news.release/cpi.t01.htm
44.
Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 47(4), 356–360 (2002).
45.
Yu TF, Gutman AB. Principles of current management of primary gout. Am. J. Med. Sci. 254(6), 893–907 (1967).
46.
Arias E. United States life tables, 2010. Natl Vital Stat. Rep. 63(7), 1–63 (2014).
47.
US Census Bureau. Current population survey, annual social and economic supplement. (2013). www.census.gov/programs-surveys/saipe/guidance/model-input-data/cpsasec.html
48.
Avalere Health Llc. Aggregate hospital payment-to-cost ratios for private payers, Medicare and Medicaid, 1994–2014. In: Trendwatch Chartbook 2016. American Hospital Association, Washington, DC, USA, 42–42 (2016).
49.
Centers for Medicare and Medicaid Services. Physician fee schedule search (2017). www.cms.gov/apps/physician-fee-schedule/license-agreement.aspx
50.
Saseen JJ, Agashivala N, Allen RR, Ghushchyan V, Yadao AM, Nair KV. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford) 51(11), 2004–2012 (2012).
Information & Authors
Information
Published In
Pages: 807 - 816
PubMed: 29792516
Copyright
© 2018 Ironwood Pharmaceuticals, Inc.
History
Received: 19 December 2017
Accepted: 25 April 2018
Published online: 24 May 2018
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective. (2018) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2017-0103
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Xiaoxia Shi, Fengchun Zheng, Quan Wan, Peipei Chai, Guilin Wang, Zhenmiao Pang, Yuedan Ma, Estimation of the current healthcare costs of gout in Liaoning Province from 2015 to 2022 based on the SHA2011 accounting system, Frontiers in Public Health, 10.3389/fpubh.2025.1646950, 13, (2025).
- Md Abu Bakar Siddiq, Tim L. Jansen, Johannes J. Rasker, What is the Place for Uricosuric Agents in Gout Management?, Current Rheumatology Reviews, 10.2174/1573397118666220308160124, 18, 4, (279-285), (2022).
- Hannah A. Blair, Emma D. Deeks, Lesinurad in hyperuricaemia of gout: a profile of its use in the EU, Drugs & Therapy Perspectives, 10.1007/s40267-018-0566-3, 34, 12, (560-566), (2018).